首页> 外文期刊>Journal of Bioinformatics and Computational Biology >COMPUTATIONAL APPROACHES FOR DRUG REPOSITIONING AND COMBINATION THERAPY DESIGN
【24h】

COMPUTATIONAL APPROACHES FOR DRUG REPOSITIONING AND COMBINATION THERAPY DESIGN

机译:药物再分配和联合治疗设计的计算方法

获取原文
获取原文并翻译 | 示例
           

摘要

Heterogeneous high-throughput biological data become readily available for various diseases. The amount of data points generated by such experiments does not allow manual integration of the information to design the most optimal therapy for a disease. We describe a novel computational workflow for designing therapy using Ariadne Genomics Pathway Studio software. We use publically available microarray experiments for glioblastoma and automatically constructed ResNet and ChemEffect databases to exemplify how to find potentially effective chemicals for glioblastoma — the disease yet without effective treatment. Our first approach involved construction of signaling pathway affected in glioblastoma using scientific literature and data available in ResNet database. Compounds known to affect multiple proteins in this pathway were found in ChemEffect database. Another approach involved analysis of differential expression in glioblastoma patients using Sub-Network Enrichment Analysis (SNEA). SNEA identified angiogenesis-related protein Cyr61 as the major positive regulator upstream of genes differentially expressed in glioblastoma. Using our findings, we then identified breast cancer drug Fulvestrant as a major inhibitor of glioblastoma pathway as well as Cyr61. This suggested Fulvestrant as a potential treatment against glioblastoma. We further show how to increase efficacy of glioblastoma treatment by finding optimal combinations of Fulvestrant with other drugs.
机译:异质性高通量生物学数据可轻松用于各种疾病。这样的实验产生的数据点的数量不允许信息的手动整合来设计针对疾病的最佳疗法。我们描述了一种使用Ariadne Genomics Pathway Studio软件设计疗法的新颖计算流程。我们使用针对胶质母细胞瘤的公开微阵列实验,并自动构建ResNet和ChemEffect数据库,以举例说明如何为胶质母细胞瘤寻找潜在有效的化学物质-该疾病尚未得到有效治疗。我们的第一种方法涉及使用科学文献和ResNet数据库中可用的数据来构建胶质母细胞瘤中受影响的信号通路。在ChemEffect数据库中找到了已知会影响该途径中多种蛋白质的化合物。另一种方法涉及使用子网络富集分析(SNEA)分析胶质母细胞瘤患者的差异表达。 SNEA将血管生成相关蛋白Cyr61鉴定为胶质母细胞瘤中差异表达基因上游的主要正调控因子。根据我们的发现,我们然后确定了乳腺癌药物Fulvestrant和Cyr61是胶质母细胞瘤途径的主要抑制剂。这表明氟维司群是抗胶质母细胞瘤的潜在治疗方法。我们进一步展示了如何通过寻找Fulvestrant与其他药物的最佳组合来提高胶质母细胞瘤治疗的效率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号